Dr. Joseph S Raccuia, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 228 Park Ave, Hoboken, NJ 07030 Phone: 917-349-0537 Fax: 646-952-7741 |
Dr. Dean Richard Cerio, M.D. Surgery - Plastic and Reconstructive Surgery Medicare: Accepting Medicare Assignments Practice Location: 79 Hudson St, Suite 700, Hoboken, NJ 07030 Phone: 201-449-1000 Fax: 201-399-2433 |
Dr. Mario Anibal Mancheno, M.D. Surgery Medicare: Medicare Enrolled Practice Location: 422 Grand Street, Hoboken, NJ 07030 Phone: 201-656-8743 Fax: 201-319-0867 |
Shannan Rae Ferrari, PA-C Surgery - Surgical Critical Care Medicare: Not Enrolled in Medicare Practice Location: 1025 Maxwell Ln, Hoboken, NJ 07030 Phone: 551-239-1770 |
News Archive
New data showing cancer treatment Avastin (bevacizumab) can extend the lives of women with advanced cervical cancer compared to chemotherapy alone has been published in the New England Journal of Medicine.
Many studies have examined motor impairments using voxel-based lesion symptom mapping (VLSM), but few are reported regarding the corresponding relationship between cerebral cortex injury and lower limb motor impairment analyzed using this technique.
Microfluidic Systems, a privately-held company, announced today that they received an award from Inc. Magazine. The Fourth Annual Exclusive List of America's Fastest-Growing Private Companies—the Inc. 5000 ranked Microfluidic Systems number 3035 with a growth rate of 68%. The list represents the most comprehensive look at the most important segment of the economy—America's independent-minded entrepreneurs.
Abviva, Inc., a biomedical company engaged in the development and commercialization of breast cancer related applications of Mammastatin, announced today that the Japanese Patent Office issued two patents on the core technology that may be used for therapeutic applications and in the Company's breast cancer risk assessment test, the Mammastatin Serum Assay (MSA).
Premature babies with serious brain hemorrhage treated with a 'brain washing' technique pioneered by Bristol researchers have shown in a 10-year follow-up study, were twice as likely to survive without severe learning disability when compared with infants given standard treatment.
› Verified 1 days ago